Journal
PERSONALIZED MEDICINE
Volume 15, Issue 2, Pages 111-115Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/pme-2017-0069
Keywords
adenocarcinoma; ALK rearrangement; small-cell lung cancer transformation; treatment and prognosis
Categories
Ask authors/readers for more resources
Driving molecular mutations such as rearrangement of ALK and EGFR mutation is present in 5-10% of nonsmall- cell lung cancer. Tyrosine kinase inhibitors have shown good efficacy and thus become the standard of care. However, tumors have developed several resistancemechanisms against tyrosine kinase inhibitors, including transformation to small-cell lung carcinoma (SCLC). Transformation to SCLC after administration of anti-EGFR in EGFR-mutated adenocarcinoma has been well documented. Similarly, it appears that the same transformation happens in ALK-rearranged adenocarcinoma after the use of anti-ALK. In fact, to date eight cases have been reported in the literature. We aimed in this paper to focus on the characteristics, prognosis and treatment of these transformed SCLC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available